$LAURUSLABS Laurus Labs – Strong Pharma Growth Story Driven by CDMO, APIs & Specialty Manufacturing

$LAURUSLABS Laurus Labs is emerging as a leading pharmaceutical and contract manufacturing company with a diversified presence across Active Pharmaceutical Ingredients (APIs), Contract Development & Manufacturing (CDMO), formulations, and specialty ingredients. The company is well-positioned to benefit from increasing global outsourcing, rising demand for high-quality pharmaceutical manufacturing, and supply-chain diversification away from China. A key growth driver for Laurus Labs is its rapidly expanding CDMO business, which is witnessing strong client additions and increasing commercial manufacturing opportunities. The company has also strengthened its presence in oncology, cardiovascular, and specialty therapeutic segments while continuing to maintain leadership in key antiretroviral APIs. Key Financial Highlights • FY26 revenue grew to approximately ₹5,700+ crore, supported by strong CDMO and formulations growth • EBITDA margins improved due to better product mix and higher capacity utilization • Net profit witnessed strong recovery as high-margin businesses contributed a larger share of revenue • CDMO segment continues to deliver robust growth with increasing commercial projects • Strong investment in manufacturing infrastructure to support future demand • Healthy balance sheet and improving return ratios driven by earnings recovery Investment Rationale • Strong beneficiary of the global pharma outsourcing trend • Rapidly growing CDMO business provides long-term revenue visibility • Diversified revenue streams across APIs, formulations, and specialty manufacturing • Expanding capacity positions the company for future growth opportunities • Improving margins and profitability after a challenging industry cycle • Well-placed to benefit from increasing global demand for reliable pharmaceutical supply chains